Opticyte
Opticyte develops the VitalO₂ device, a medical device that provides real-time measurement of cellular and blood oxygen levels to help clinicians detect and treat sepsis, trauma, and respiratory failure. Its technology is designed to deliver accurate results for all skin tones, addressing disparities in current pulse oximetry and aiming to reduce organ failure and death. Opticyte's mission is to bring greater equity to healthcare and improve outcomes for critically ill patients.
Facts
- Sectors
- Medical device, Healthcare, Diagnostics
- Founded
- 2016 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Opticyte Inc Seattle business license
- Total raised
- $72.3K SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $72.3K · Sep 2017 SEC Form D
- Founders
- Lori Arakaki, PhD
Is this your organization? Claim it
Opticyte raises $4.6M to test real-time Cell O2 Monitor for early sepsis-induced organ failure
UW spinout Opticyte raised $4.6 million — $2.9M in federal grants and $1.7M in seed funding — to test a non-invasive Cell O2 Monitor that measures cellular oxygen in real time to detect early organ failure from sepsis. The company will begin an observational study at Harborview Medical Center in May or June and use funding to hire staff and continue device development.
People
-
Lori Arakaki Executive, CEO
